Author/Editor		Burja, Blaž; Hočevar, Alojzija; Sodin-Šemrl, Snežna; Lakota, Katja; Rotar, Žiga; Ješe, Rok; Žigon, Polona; Čučnik, Saša; Praprotnik, Sonja; Tomšič, Matija
Title		Zgodnji gigantocelični arteritis
Translated title		Early giant cell arteritis
Type		članek
Vol. and No.		Letnik 87, št. 7/8
Publication year		2018
Volume		str. 335-348
ISSN		1581-0224 - Zdravniški vestnik
Language		slv
Abstract		Giant cell arteritis (GCA) is the most prevalent primary systemic vasculitis in adults over 50 ye - ars of age in Europe. It affects large and medium sized arteries; the inflammatory process can ultimately lead to stenosis or occlusion of arterial lumen, resulting in severe clinical complica- tions. In the last decade, imaging in diagnostics has importantly shortened the time to disease recognition (e.g. early GCA). Fast track clinics have led to a decrease in appearance of the most severe ischemic disease complications and lower costs of therapy. Despite fast access to approp - riate therapy, the disease is chronic, and patients can experience relapses, which together with glucocorticoid therapy may lead to organ and tissue damage. Therefore, viable molecular and cellular target therapies are intensely explored. The major aims of our review were to: a) identify studies with indicated time from symptom development to diagnosis, b) explore promising molecular targets for GCA therapy, and c) identify clinically-relevant cellular phenotypes. The most promising molecular targets are IL-6, IL-12/IL-23, cytotoxic T-lymphocyte-associated protein-4, while therapies against TNF-[alpha] showed limited value and no clinical studies with secukimumab targeting IL-17 in GCA have been reported to date. Potential future therapeutic targets have been discussed, including targets in signaling pathways.
Keywords		zgodnji gigantocelični arteritis biološki označevalci tarčno zdravljenje early giant cell arteritis biomarkers therapy targets